Literature DB >> 16284554

Safety of heparinization for cerebral aneurysm coiling soon after external ventriculostomy drain placement.

Brian L Hoh1, Raul G Nogueira, Carlos J Ledezma, Johnny C Pryor, Christopher S Ogilvy.   

Abstract

OBJECTIVE: Our practice has been to heparinize patients for cerebral aneurysm coiling even after recent external ventriculostomy drain (EVD) placement. The current medical literature cites a 12.5% symptomatic hemorrhage rate with heparinization after recent EVD placement. We reviewed our experience to determine our level of safety with this practice.
METHODS: A search of our prospectively collected computerized aneurysm database revealed that from February 1998 to February 2004, 356 aneurysms were coiled, of which 119 patients had had recent EVD placement before coiling. During the same time period, 251 subarachnoid hemorrhage patients underwent EVD placement without coiling or heparinization. We reviewed the head computed tomographic scan reports and medical records to determine the incidence of EVD-related hemorrhage in heparinized patients compared with nonheparinized patients.
RESULTS: There was only 1 patient in the heparinized group who had a symptomatic EVD-related hemorrhage attributable to heparinization (0.8%) and 11 patients with asymptomatic EVD-related hemorrhage (9.2%). Among the nonheparinized patients, there were 3 patients who had symptomatic EVD-related hemorrhages (1.2%) and 22 patients with asymptomatic EVD-related hemorrhages (8.8%) (P = not significant for both symptomatic and asymptomatic EVD-related hemorrhages). The time interval between EVD placement and heparinization in the heparinized patient with symptomatic EVD-related hemorrhage was 0.5 day; the mean time interval in the heparinized patients with asymptomatic EVD-related hemorrhage was 0.8 day; and in the heparinized patients with no hemorrhage, it was 0.8 day. The peak activated prothrombin time of the heparinized patient with symptomatic EVD-related hemorrhage was >150 seconds, the mean peak activated prothrombin time of the heparinized patients with asymptomatic EVD-related hemorrhage was 73.1 seconds, and that of the heparinized patients with no hemorrhage was 90.3 seconds.
CONCLUSION: Heparinization for cerebral aneurysm coiling can be safely performed even after EVD placement within 24 hours, particularly if the activated prothrombin time is kept strictly controlled.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16284554     DOI: 10.1227/01.neu.0000180814.95032.07

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  15 in total

1.  Hemorrhage Rate After External Ventricular Drain Placement in Subarachnoid Hemorrhage: Time to Heparin Administration.

Authors:  Andrew P Gard; Brian D Sayles; J Will Robbins; William E Thorell; Daniel L Surdell
Journal:  Neurocrit Care       Date:  2017-12       Impact factor: 3.210

Review 2.  Clinical Presentation, Imaging, and Management of Complications due to Neurointerventional Procedures.

Authors:  Matthew C Davis; John P Deveikis; Mark R Harrigan
Journal:  Semin Intervent Radiol       Date:  2015-06       Impact factor: 1.513

3.  Bleeding and infection with external ventricular drainage: a systematic review in comparison with adjudicated adverse events in the ongoing Clot Lysis Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III (CLEAR-III IHV) trial.

Authors:  Mahua Dey; Agnieszka Stadnik; Fady Riad; Lingjiao Zhang; Nichol McBee; Carlos Kase; J Ricardo Carhuapoma; Malathi Ram; Karen Lane; Noeleen Ostapkovich; Francois Aldrich; Charlene Aldrich; Jack Jallo; Ken Butcher; Ryan Snider; Daniel Hanley; Wendy Ziai; Issam A Awad
Journal:  Neurosurgery       Date:  2015-03       Impact factor: 4.654

4.  Risk of Ventriculostomy-Associated Hemorrhage in Patients with Aneurysmal Subarachnoid Hemorrhage Treated with Anticoagulant Thromboprophylaxis.

Authors:  Joseph Zachariah; Kendall A Snyder; Christopher S Graffeo; Deependra R Khanal; Giuseppe Lanzino; Eelco F M Wijdicks; Alejandro A Rabinstein
Journal:  Neurocrit Care       Date:  2016-10       Impact factor: 3.210

5.  The Incidence of Catheter Tract Hemorrhage and Catheter Placement Accuracy in the CLEAR III Trial.

Authors:  Achim Müller; W Andrew Mould; W David Freeman; Nichol McBee; Karen Lane; Rachel Dlugash; Rick Thompson; Saman Nekoovaght-Tak; Vikram Madan; Hasan Ali; Agnieszka Stadnik; Issam Awad; Daniel Hanley; Wendy C Ziai
Journal:  Neurocrit Care       Date:  2018-08       Impact factor: 3.210

6.  Hemorrhagic Complications Associated with Ventriculostomy in Patients Undergoing Endovascular Treatment for Intracranial Aneurysms: A Single-Center Experience.

Authors:  Jack M Leschke; Andrew Lozen; Mayank Kaushal; Akinwunmi Oni-Orisan; Mazen Noufal; Osama Zaidat; Glen A Pollock; Wade M Mueller
Journal:  Neurocrit Care       Date:  2017-08       Impact factor: 3.210

Review 7.  Blood Flow Diversion as a Primary Treatment Method for Ruptured Brain Aneurysms-Concerns, Controversy, and Future Directions.

Authors:  Brian P Walcott; Matthew J Koch; Christopher J Stapleton; Aman B Patel
Journal:  Neurocrit Care       Date:  2017-06       Impact factor: 3.210

8.  Intra-Arterial Eptifibatide in the Management of Thromboembolism during Endovascular Treatment of Intracranial Aneurysms: Case Series and a Review of the Literature.

Authors:  Pankajavalli Ramakrishnan; Albert J Yoo; James D Rabinov; Christopher S Ogilvy; Joshua A Hirsch; Raul G Nogueira
Journal:  Interv Neurol       Date:  2013-10

9.  Venous Thromboembolism After Intraventricular Hemorrhage: Results From the CLEAR III Trial.

Authors: 
Journal:  Neurosurgery       Date:  2019-03-01       Impact factor: 4.654

Review 10.  Prophylaxis of Venous Thrombosis in Neurocritical Care Patients: An Evidence-Based Guideline: A Statement for Healthcare Professionals from the Neurocritical Care Society.

Authors:  Paul Nyquist; Cynthia Bautista; Draga Jichici; Joseph Burns; Sanjeev Chhangani; Michele DeFilippis; Fernando D Goldenberg; Keri Kim; Xi Liu-DeRyke; William Mack; Kim Meyer
Journal:  Neurocrit Care       Date:  2016-02       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.